The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Perhaps the answer is in your below post.$10? I should pay more attention when reading. So will all shares be issued with nominal value of $10 including those to hit the exchange? Then what value will they have on day 1 listing?
Oak I can't anything in rns ' s that tells us the nominal value of the shares to be issued to ciz on exercise of the out option. I would assume it would be equal to the shares to be listed (are they at par or premium). I suppose what I'm saying is conduit shares would need to rise in value post listing for ciz to profit on this (aside from the 1m£ or so increase in the value of azd since ciz acquired). Realistically I would expect only to get 3.25m should the put option be exercised and shares then sold by ciz in short timefram
Google reports a day high of133 but not showing on lse. Perhaps an error
This feels like good news
Due soon. Released on 12 August last year
Cebo. Prior to 14th June they held 5.9% of voting rights via financial instruments, 14th June they hold 9.9% of voting rights via shares held. They no longer hold voting rights via financial instruments- what has triggered this change?
Is that a debt to equity conversion on todays rns? Previously had 6% interest via financial instruments, now has just under 10% ordinary share capital
Odeys short may not be gone but it has reduced on two successive days
Sure but if they recycle the cash into say a mortgage loan the cash asset would become a debtor asset
Deposits are generally neutral on the BS. Book a liability to the customer, cash is the asset.
Sure interest payments shelter profits to an extent but its still an expense so you would rather not pay it. I think you are probably thinking of ahareholder debt being a good thing (lending down the corporate chain). Thing to note is there are many barriers to actually taking a deduction for interest expense such as anti hybrid, transfer pricing, corporate interest restriction and late paid interest rules.
Do you mean this?
https://twitter.com/marcopabst/status/1659137067152965632?t=ky4s1OPHOoOJPzSHlYFP9g&s=19
Solid. Check out q1 22 trading update. No profit/ revenue figures. I would say this is consistent with previous behaviour and not trying trying hide anything. H1 results will have it all. A couple of months away.
Cyberdog. How do you reach that conclusion with such confidence? Metro has been waiting for an opportunity to profit from high interest rates. Do you not think they will increase the NIM and profit from it? No investment arm to ruin the good work of the retail bank. What about the statements in the last 2 trading updates where they say they are profitable q4 22 and q1 23? Can they not be believed... sure we can only speculate on profits achieved ytd, but I am am taking a positive view on the increase in base rate.... perhaps I am believing only what I want to because I have shoved cash in here. Time will tell. H1 results will settle this.
No short position in 888 reported on fca today
Have taken a few quid here today. Debt extremely high. Have watched cineworld with caution recently over 5bn of debt unable to service. However given the loan terms interest payments look manageable for 888 barring unforseen events. Thanks for pointing out director buys. Certainly some confidence given the level of cash invested.
Sat on the sidelines doing a bit of research. Is the debt pile going to be a problem? Virtually none to 2bn in a matter of a year. Is there a risk that tighter regulation will impact revenue in the long run?
Fca short tracker showing odeys position at 3.67 dated 13.02 and no reduction in ubs. Weird. Odey reduced to 2.24 since then.
Cheers JJ. Have a good day
I got the short reduction wrong. No change.... Interestingly Google search results show q1 23 trading update as 3 may but this is not showing in metrobank investor relations